Comparing Bimekizumab vs Secukinumab
| Bimekizumab | Secukinumab |
|
|---|
| Bimekizumab | Secukinumab |
|
|---|---|---|
|
Prescription only
Prescribed for Psoriatic Arthritis, Hidradenitis Suppurativa, Ankylosing Spondylitis, Non-Radiographic Axial Spondyloarthritis, Plaque Psoriasis. Bimekizumab may also be used for purposes not listed... View more |
Prescription only
Prescribed for Hidradenitis Suppurativa, Enthesitis-Related Arthritis, Ankylosing Spondylitis, Non-Radiographic Axial Spondyloarthritis, Plaque Psoriasis, Psoriasis, Psoriatic Arthritis. Secukinumab... View more |
Related suggestions |
| More about Bimekizumab | More about Secukinumab | |
| Ratings & Reviews | ||
|
Bimekizumab has an average rating of 8.4 out of 10 from a total of 17 ratings on Drugs.com. 71% of reviewers reported a positive effect, while 0% reported a negative effect. |
Secukinumab has an average rating of 6.3 out of 10 from a total of 260 ratings on Drugs.com. 52% of reviewers reported a positive effect, while 30% reported a negative effect. |
|
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||
|
View all Bimekizumab side effects |
View all Secukinumab side effects |
|
| Drug Class | ||
| Generic Availability | ||
|
N/A |
N/A |
|
| Pricing and Coupons * Prices are without insurance | ||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
|
| Dosage Forms | ||
|
N/A |
N/A |
|
| Brand Names | ||
| Bimzelx | Cosentyx | |
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||
|
552 hours |
744 hours |
|
| CSA Schedule 1 View glossary of CSA terms | ||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
|
| Pregnancy Category | ||
|
Summary unavailable. See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
|
| Drug Interactions | ||
|
A total of 311 drugs are known to interact with Bimekizumab:
|
A total of 249 drugs are known to interact with Secukinumab:
|
|
| Alcohol/Food/Lifestyle Interactions | ||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
| Disease Interactions | ||
| First Approval Date | ||
|
October 17, 2023 |
January 21, 2015 |
|
| WADA Class View classifications | ||
|
N/A |
N/A |
|
| More Information | ||
| Patient Resources | ||
| Professional Resources | ||
| Related Treatment Guide | ||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Skyrizi
Skyrizi (risankizumab) is used to treat plaque psoriasis, psoriatic arthritis, ulcerative colitis ...
Stelara
Stelara (ustekinumab) is used to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and ...
Otezla
Otezla (apremilast) is used to treat plaque psoriasis, psoriatic arthritis, and oral ulcers ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Vtama
Vtama (tapinarof) is a steroid-free, once-daily cream used to treat plaque psoriasis and atopic ...
Celebrex
Celebrex is a nonsteroidal anti-inflammatory drug used to treat pain or inflammation. Learn about ...
Humira
Humira is a tumor necrosis factor blocker that is used to treat many inflammatory conditions such ...
Medrol
Medrol is used for allergic rhinitis, asthma, asthma, acute, asthma, maintenance, congenital ...
Rinvoq
Rinvoq (upadacitinib) is used to treat rheumatoid arthritis, psoriatic arthritis, atopic ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.